ERBB2 and cancer: One of the humanized versions of this antibody named humAb4D5-8, later named trastuzumab, showed a four-fold increase in HER2 binding affinity compared to the parental mumAb4D5, similar cytostatic activity, and more efficient ADCC against HER2 overexpressing cancer cells.